Home›Trial›NCT06420297
NCT06420297Phase 3ENROLLING BY INVITATION

OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

Study Summary

To evaluate long-term safety and tolerability of carbetocin nasal spray (3.2 mg TID) in subjects with PWS

Conditions
Hyperphagia in Prader-Willi Syndrome
Interventions / Drugs
Carbetocin
View on ClinicalTrials.gov ↗
Sponsor
ACAD
ACADIA Pharmaceuticals
Neuroscience
B77/100
Study Details
Enrollment160 participants
Primary Completion—
Lead SponsorACADIA Pharmaceuticals Inc.
Data Retrieved2026-04-11 02:52:05.277017+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

Phase 3 trials are pivotal studies with large patient populations (hundreds to thousands) designed to prove efficacy and safety for FDA submission. A successful Phase 3 readout is typically the last major hurdle before a New Drug Application (NDA) or BLA filing.

Status & Expected Data

Current status: ENROLLING BY INVITATION.

Enrolled: 160 participants
Sponsor Catalyst Profile

ACADIA Pharmaceuticals (ACAD) is the sponsoring company for this trial. BiotechSign currently grades this company B (77/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

ACAD Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.